Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL27207863 | 1.00 | CA2 (0.46) | — | |
| Phosphoric Acid SCHEMBL28868579 | 1.00 | CA2 (0.46) | — | |
| Phosphoric Acid SCHEMBL28268189 | 1.00 | CA2 (0.46) | — | |
| Phosphoric Acid SCHEMBL28915056 | 1.00 | CA2 (0.46) | — | |
| Phosphoric Acid SCHEMBL738836 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL6251825 | 1.00 | CA2 (0.46) | — | |
| Phosphoric Acid SCHEMBL28821712 | 1.00 | CA2 (0.46) | — | |
| Phosphoric Acid SCHEMBL3623169 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL21596294 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL3143227 | 0.94 | CA2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116920172-A | Collagen fiber-biological ceramic composite artificial bone and preparation method thereof | 深圳大洲医学科技有限公司 | 2023-10-24 | — | — | CN | claimed |
| EP-0143413-B1 | DIGITALIS ANTIBODIES, METHOD OF PREPARATION AND THEIR USE IN THERAPY OF DIGITALIS INTOXICATION | Roche Diagnostics GmbH (DE) | 1991-06-05 | — | — | EP | claimed |
| US-4742159-A | Digitalis antibodies, process for the preparation thereof and the use thereof for the therapy of digitalis intoxications | BOEHRINGER MANNHEIM GMBH (DE) | 1988-05-03 | — | — | US | claimed |
| JP-5281234-A | — | — | None | — | — | JP | disclosed |
| US-20240209422-A1 | HYBRIDIZATION COMPOSITIONS AND METHODS USING FORMAMIDE | DAKO DENMARK APS (DK) | 2024-06-27 | — | — | US | disclosed |
| EP-4378484-A2 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY | Millennium Pharmaceuticals, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-4378959-A2 | FORMULATION FOR ANTI-ALPHA4BETA7 ANTIBODY | Millennium Pharmaceuticals, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20240018590-A1 | HYBRIDIZATION COMPOSITIONS AND METHODS | DAKO DENMARK APS (DK) | 2024-01-18 | — | — | US | disclosed |
| US-20230416395-A1 | ANTI-CD38 ANTIBODIES AND FORMULATIONS | SANOFI (FR) | 2023-12-28 | — | — | US | disclosed |
| EP-4295917-A2 | TRANS-CYCLOOCTENE BIOORTHOGONAL AGENTS AND USES IN CANCER AND IMMUNOTHERAPY | Tambo, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-116920172-A | Collagen fiber-biological ceramic composite artificial bone and preparation method thereof | 深圳大洲医学科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| WO-1990011128-A1 | POLYMER-COATED NOBLE METAL PARTICLES AND A METHOD FOR THEIR PREPARATION | VINTEN JOERGEN C AA (DK) | 1990-10-04 | — | — | WO | disclosed |
| EP-0376931-A1 | Process for making collagen membranous materials for medical use | COLLAGEN CORPORATION (US) | 1990-07-04 | — | — | EP | disclosed |
| WO-1990005296-A1 | ELECTROCHEMILUMINESCENT REACTION UTILIZING AMINE-DERIVED REDUCTANT | IGEN, INC. (US) | 1990-05-17 | — | — | WO | disclosed |
| WO-1990005302-A1 | ENHANCED ELECTROCHEMILUMINESCENCE | IGEN, INC. (US) | 1990-05-17 | — | — | WO | disclosed |
| US-4925652-A | NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-05-15 | — | — | US | disclosed |
| EP-0363703-A1 | Method of producing human-human hybridomas, the production of monoclonal and polyclonal antibodies therefrom, and therapeutic use thereof | Alonso, Kenneth (US) | 1990-04-18 | — | — | EP | disclosed |
| US-4845090-A | NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-07-04 | — | — | US | disclosed |
| US-4725671-A | Collagen membranes for medical use | COLLAGEN CORPORATION (US) | 1988-02-16 | — | — | US | disclosed |
| EP-0187014-A2 | Process for making collagen membranes for medical use | COLLAGEN CORPORATION (a Delaware corporation) (US) | 1986-07-09 | — | — | EP | disclosed |